

Sedative / Hypnotics

Point-of-Sale (POS) edits are safety limitations that are automatically verified through computer programming at the time that a prescription claim is submitted at the pharmacy. These edits can be applied to *any* medication, whether or not it is listed in the Preferred Drug List / Non-Preferred Drug List (PDL/NPDL). The first section of this document is organized to follow the order of the therapeutic classes in the PDL/NPDL and explains the POS edits for those medications.

POS Abbreviations

AL – Age Limit	DD – Drug-Drug Interaction	MD – Maximum Dose Limit	TD - Therapeutic Duplication
BH – Behavioral Health Clinical Authorization for Children Younger than 7 Years of Age	DS Maximum Days’ Supply Allowed	PR – Enrollment in a Physician-Supervised Program Required	UN – Drug Use Not Warranted
BY – Diagnosis Codes Bypass Some Requirements	DT – Duration of Therapy Limit	PU – Prior Use of Other Medication is Required	X – Prescriber Must Have ‘X’ DEA Number
CL – Additional Clinical Information is Required	DX – Diagnosis Code Requirement	QL – Quantity Limit	YQ – Yearly Quantity Limit
CU – Concurrent Use with Other Medication is Restricted	ER – Early Refill	RX – Specific Prescription Requirement	

Pharmacy Prior Authorization Phone Numbers for MCOs and FFS

Aetna Better Health of Louisiana **1-855-242-0802**

AmeriHealth Caritas Louisiana **1-800-684-5502**

Fee-for-Service (FFS) Louisiana Legacy Medicaid **1-866-730-4357**

Healthy Blue **1-844-521-6942**

Louisiana Healthcare Connections **1-888-929-3790**

UnitedHealthcare **1-800-310-6826**

Sedative / Hypnotics

POS Edits

BH — Additional behavioral health related clinical information (trial of behavioral therapy, etc.) is required for doxepin when requested for recipients who are younger than 7 years of age.

BY — Pharmacy claims for sedative/hypnotics submitted with a diagnosis code for palliative end-of-life care (Z51.5), will bypass the quantity limits.

CL — Additional clinical information (prescriber specialty, severity of diagnosis, etc.) is required for tasimelteon.

MD — Sedative/hypnotics have a maximum daily dose as listed in the chart to the right.	Maximum Daily Dose for Selected Sedative/Hypnotics	
	Generic Name (Brand Example)	Maximum Dose Per Day
	<u>Daridorexant (Quviviq™)</u>	<u>50 mg/day</u>
	Doxepin (Silenor®)	6 mg/day
	Estazolam (ProSom®)	2 mg/day
	Eszopiclone (Lunesta®)	3 mg/day
	Flurazepam (Dalmane®)	30 mg/day
	Lemborexant (Dayvigo®)	10 mg/day
	Quazepam (Doral®)	15 mg/day
	Ramelteon (Rozerem®)	8 mg/day
	Suvorexant (Belsomra®)	20mg/day
	Tasimelteon (Hetlioz®)	20mg/day
	Temazepam (Restoril®)	30 mg/day
	Triazolam (Halcion®)	0.5 mg/day
	Zaleplon (Sonata®)	20 mg/day
	Zolpidem IR tablet (Ambien®)	10 mg/day
	Zolpidem SL tablet (Edluar®)	10 mg/day
	Zolpidem Oral Spray (ZolpiMist®)	10 mg (2sprays)/day
	Zolpidem ER Tablet (Ambien CR®)	12.5 mg/day
	Zolpidem SL Tablet (Intermezzo®)	1.75mg/day (female)
	Zolpidem SL Tablet (Intermezzo®)	3.5 mg/day (male)

- QL**
- Pharmacy claims for all sedative/hypnotic agents (except tasimelteon capsule and zolpidem oral spray) are limited to:
 - A quantity of 7 per rolling 30 days for recipients who have no sedative/hypnotic pharmacy claims in the previous 60-day period
 - A quantity of 15 per rolling 30 days for recipients who have any sedative/hypnotic pharmacy claim in the previous 60-day period
 - Tasimelteon (Hetlioz LQ™) is limited to a maximum quantity of 1580 ml per 310 days.

TD — These agents are monitored at the pharmacy POS for duplication of therapy with other sedative/hypnotic agents.

Sedative / Hypnotics

Revision / Date	Implementation Date
Created POS Document	February 2020
Added Dayvigo™ POS edits (including quantity limit) / July 2020	October 2020
Added quantity limits to all other sedative/hypnotics (except Hetlioz® and ZolpiMist®) / September 2020	January 2021
Modified to apply new age requirement for behavioral health clinical authorization / November 2020	January 2021
Added Hetlioz LQ™ / May 2021	October 2021
Modified quantity limit for Dayvigo® / June 2021	January 2022
<u>Added Quvivig™, policy clarifications / June 2022</u>	<u>January 2023</u>